St Andrews Research Repository

St Andrews University Home
View Item 
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  • Register / Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

The genetic contribution of the NO system at the glutamatergic post-synapse to schizophrenia : further evidence and meta-analysis

Thumbnail
View/Open
NOS1_at_the_glutamatergic_postsynapse_in_schizophrenia_accepted.pdf (1.338Mb)
Date
01/2014
Author
Weber, H.
Klamer, D.
Freudenberg, F.
Kittel-Schneider, S.
Rivero, O.
Scholz, C. -J.
Volkert, J.
Kopf, J.
Heupel, J.
Herterich, S.
Adolfsson, R.
Alttoa, A.
Post, A.
Grussendorf, H.
Kramer, A.
Gessner, A.
Schmidt, B.
Hempel, S.
Jacob, C. P.
Sanjuan, J.
Molto, M. D.
Lesch, K. -P.
Freitag, C. M.
Kent, L.
Reif, A.
Keywords
Glutamate
Nitric oxide
Association
Schizophrenia
Post-synapse
Prefrontal cortex
RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
SDG 3 - Good Health and Well-being
Metadata
Show full item record
Abstract
NO is a pleiotropic signaling molecule and has an important role in cognition and emotion. In the brain, NO is produced by neuronal nitric oxide synthase (NOS-I, encoded by NOS1) coupled to the NMDA receptor via PDZ. interactions; this protein-protein interaction is disrupted upon binding of NOS1 adapter protein (encoded by NOS1AP) to NOS-I. As both NOS1 and NOS1AP were associated with schizophrenia, we here investigated these genes in greater detail by genotyping new samples and conducting a meta-analysis of our own and published data. In doing so, we confirmed association of both genes with schizophrenia and found evidence for their interaction in increasing risk towards disease. Our strongest finding was the NOS1 promoter SNP rs41279104, yielding an odds ratio of 1.29 in the meta-analysis. As findings from heterologous cell systems have suggested that the risk allele decreases gene expression, we studied the effect of the variant on NOS1 expression in human post-mortem brain samples and found that the risk allele significantly decreases expression of NOS1 in the prefrontal cortex. Bioinformatic analyses suggest that this might be due the replacement of six transcription factor binding sites by two new binding sites as a consequence of proxy SNPs. Taken together, our data argue that genetic variance in NOS1 resulting in lower prefrontal brain expression of this gene contributes to schizophrenia liability, and that NOS1 interacts with NOS1AP in doing so. The NOS1-NOS1AP PDZ interface may thus well constitute a novel target for small molecules in at least some forms of schizophrenia. 
Citation
Weber , H , Klamer , D , Freudenberg , F , Kittel-Schneider , S , Rivero , O , Scholz , C -J , Volkert , J , Kopf , J , Heupel , J , Herterich , S , Adolfsson , R , Alttoa , A , Post , A , Grussendorf , H , Kramer , A , Gessner , A , Schmidt , B , Hempel , S , Jacob , C P , Sanjuan , J , Molto , M D , Lesch , K -P , Freitag , C M , Kent , L & Reif , A 2014 , ' The genetic contribution of the NO system at the glutamatergic post-synapse to schizophrenia : further evidence and meta-analysis ' , European Neuropsychopharmacology , vol. 24 , no. 1 , pp. 65-85 . https://doi.org/10.1016/j.euroneuro.2013.09.005
Publication
European Neuropsychopharmacology
Status
Peer reviewed
DOI
https://doi.org/10.1016/j.euroneuro.2013.09.005
ISSN
0924-977X
Type
Journal article
Rights
Copyright 2014 Elsevier B.V. and ECNP. All rights reserved. This is the author’s version of a work that was accepted for publication in European Neuropsychopharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in European Neuropsychopharmacology, 24, 1, January 2014 DOI 10.1016/j.euroneuro.2013.09.005
Collections
  • University of St Andrews Research
URI
http://hdl.handle.net/10023/6401

Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

Advanced Search

Browse

All of RepositoryCommunities & CollectionsBy Issue DateNamesTitlesSubjectsClassificationTypeFunderThis CollectionBy Issue DateNamesTitlesSubjectsClassificationTypeFunder

My Account

Login

Open Access

To find out how you can benefit from open access to research, see our library web pages and Open Access blog. For open access help contact: openaccess@st-andrews.ac.uk.

Accessibility

Read our Accessibility statement.

How to submit research papers

The full text of research papers can be submitted to the repository via Pure, the University's research information system. For help see our guide: How to deposit in Pure.

Electronic thesis deposit

Help with deposit.

Repository help

For repository help contact: Digital-Repository@st-andrews.ac.uk.

Give Feedback

Cookie policy

This site may use cookies. Please see Terms and Conditions.

Usage statistics

COUNTER-compliant statistics on downloads from the repository are available from the IRUS-UK Service. Contact us for information.

© University of St Andrews Library

University of St Andrews is a charity registered in Scotland, No SC013532.

  • Facebook
  • Twitter